Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Alfred Yung

Showing results (171-180 of 217) with videos related to

Pageof 22
Sort By:
Journal of Neuro-Oncology|November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastomaMartin van den Bent, Analia Azaro, Filip De Vos, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Genes & Development|June 26, 2013
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survivalSiyuan Zheng, Jun Fu, Rahulsimham Vegesna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Cancer|October 26, 2018
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastomaStefania Maraka, Morris D Groves, Aaron G Mammoser, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Pageof 22

Showing results (171-180 of 217) with videos related to

Sort By:
Pageof 22
Journal of Neuro-Oncology|November 29, 2019
A Phase Ib/II, open-label, multicenter study of INC280 (capmatinib) alone and in combination with buparlisib (BKM120) in adult patients with recurrent glioblastomaMartin van den Bent, Analia Azaro, Filip De Vos, et al.
Neuro-Oncology|November 1, 2020
Radiographic read paradigms and the roles of the central imaging laboratory in neuro-oncology clinical trialsBenjamin M Ellingson, Matthew S Brown, Jerrold L Boxerman, et al.
Genes & Development|June 26, 2013
A survey of intragenic breakpoints in glioblastoma identifies a distinct subset associated with poor survivalSiyuan Zheng, Jun Fu, Rahulsimham Vegesna, et al.
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|May 25, 2011
Phase II study of aflibercept in recurrent malignant glioma: a North American Brain Tumor Consortium studyJohn F de Groot, Kathleen R Lamborn, Susan M Chang, et al.
Cancer|October 26, 2018
Phase 1 lead-in to a phase 2 factorial study of temozolomide plus memantine, mefloquine, and metformin as postradiation adjuvant therapy for newly diagnosed glioblastomaStefania Maraka, Morris D Groves, Aaron G Mammoser, et al.
Neuro-Oncology|August 5, 2011
Is surgery at progression a prognostic marker for improved 6-month progression-free survival or overall survival for patients with recurrent glioblastoma?Jennifer L Clarke, Michele M Ennis, W K Alfred Yung, et al.
Journal of Neuro-Oncology|June 30, 2009
Phase II trials of erlotinib or gefitinib in patients with recurrent meningiomaAndrew D Norden, Jeffrey J Raizer, Lauren E Abrey, et al.
Journal of Neuro-Oncology|October 9, 2017
Phase I study of sorafenib and tipifarnib for recurrent glioblastoma: NABTC 05-02Phioanh Leia Nghiemphu, Victoria Asuquo Ebiana, Patrick Wen, et al.
Journal of Neuro-Oncology|February 7, 2018
NRG oncology RTOG 9006: a phase III randomized trial of hyperfractionated radiotherapy (RT) and BCNU versus standard RT and BCNU for malignant glioma patientsArif N Ali, Peixin Zhang, W K Alfred Yung, et al.
Neuro-Oncology|February 13, 2010
A phase I trial of erlotinib in patients with nonprogressive glioblastoma multiforme postradiation therapy, and recurrent malignant gliomas and meningiomasJeffrey J Raizer, Lauren E Abrey, Andrew B Lassman, et al.
Pageof 22